| http://www.w3.org/ns/prov#value | - Since the establishment of this act (i.e., 1997 FDAMA),3 the FDA has worked closely and diligently with professional associations, manufacturers, and other interested persons (e.g., patient advocacy groups and physicians and scientists licensed to make or use PET drugs, etc.) to develop PET drug approval procedures (i.e., NDA and ANDA), as well as CGMP regulations specifically for PET drugs.
|
